The Federal Court has continued its run of decisions on contested costs orders. The cost of litigating patent disputes in the Federal Court is high. To maximise the costs recovered, parties are issuing Notices of Offer (pursuant to the Federal Court Rules) and Calderbank letters. These are designed to put the other party at risk of an indemnity costs order should they reject the offer and the first party ultimately receives a more favourable judgment. Indemnity costs orders enable a successful party to claw back up to 100% of their legal costs, whereas a party/party costs order typically only provides a successful party with around 60% of their actual legal costs. So, significant sums of money can be at stake as a result of an effective or ineffective Notice of Offer or Caldberank letter.
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Pearce IP BioBlast® for the week ending 20 September 2024
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe...
When things go wrong: “Obvious Mistake” Results in CRISPR Patent Application Amendment
The battle to claim the earliest valid patent rights to CRISPR gene-editing technology has been fought around the world. In Australia, the most protracted dispute…
Pearce IP BioBlast® for the week ending 13 September 2024
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September...
Pearce IP BioBlast® for the fortnight ending 06 September 2024
Adalimumab 1 September 2024 | AU | Pfizer’s Biosimilar Adalimumab PBS-Listed in Australia On 1 September 2024, the PBS...
Generic Partners & Apotex Infringe valid Neurim Sleep Patent
CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.
Pearce IP BioBlast® for w/e 16 August 2024
16 August 2024 | AU | Janssen Sues Samsung Bioepis for Patent Infringement in Australian Court On 16 August 2024,...
Pearce IP BioBlast® for w/e 09 August 2024
9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results - 37% Biosimilar Growth On 9 August 2024, Sandoz...
Pearce IP BioBlast® for w/e 02 August 2024
2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s...
Pearce IP BioBlast® for w/e 26 July 2024
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie...
Pearce IP BioBlast® for w/e 19 July 2024
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that...
Pearce IP BioBlast for w/e 12 July 2024
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...
Elanco Sheepish as Patent Application Not Inventive
Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640
Pearce IP BioBlast for w/e 05 July 2024
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical...
Pearce IP BioBlast for fortnight ending 28 June 2024
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech...
Pearce IP BioBlast for fortnight ending 14 June 2024
14 June 2024 | AU | Approval Alert: Bayer’s High Dose Eylea® (aflibercept) Approved in Australia On 14 June 2024,...